Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 21, 2021 - Issue 9
Submit an article Journal homepage
539
Views
3
CrossRef citations to date
0
Altmetric
Drug Evaluation

Lisocabtagene Maraleucel for the treatment of B-cell lymphoma

Chaitanya Iragavarapua Assistant Professor of Medicine, Division of Hematology & Blood and Marrow Transplantation, University of Kentucky, Markey Cancer Center, Lexington, KY, USAView further author information
&
Gerhard Hildebrandtb Professor of Medicine, Division Chief, Hematology & Blood and Marrow Transplantation;c Director, Blood and Marrow Transplant and Cellular Therapy Program;d Adjunct Professor, Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Markey Cancer Center, Lexington, KY, USACorrespondence[email protected]
View further author information
Pages 1151-1156 | Received 21 Jan 2021, Accepted 20 May 2021, Published online: 28 Jun 2021

References

  • Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016 Feb;30(2):492–500.
  • Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020 Sep 19;396(10254):839–852.
  • Gross G, Gorochov G, Waks T, et al. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc. 1989 Feb;21(1 Pt 1):127–130.
  • Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 1995 Aug 1;55(15):3369–3373.
  • Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002 Feb;20(2):143–148.
  • Zola H, MacArdle PJ, Bradford T, et al. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol. 1991 Dec;69(6):411–422.
  • Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+: CD8+composition in adult B cell ALL patients. J Clin Invest. 2016 Jun 1;126(6):2123–2138.
  • Hirayama AV, Gauthier J, Hay KA, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019 Apr 25;133(17):1876–1887.
  • Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017 Oct 19;130(16):1800–1808.
  • Sehgal AR, Hildebrandt G, Ghosh N, et al. Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): updated results from the PILOT study. Vaccine. 2020;38(50):8040.
  • Bachier CR, Godwin JE, Andreadis C, et al. Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). 2020;38(15_suppl):8037–8037.
  • Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019 Jan 3;380(1):45–56.
  • Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015 Jun;21(6):581–590.
  • Zhang H, Snyder KM, Suhoski MM, et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol. 2007 Oct 1;179(7):4910–4918.
  • Oo O, Jp J, VW L, et al. Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/refractory large B Cell lymphoma. Biol Blood Marrow Transplant. 2020 Sep;26(9):1581–1588.
  • Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Jan;20(1):31–42.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.